RS55377B1 - Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-a - Google Patents
Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-aInfo
- Publication number
- RS55377B1 RS55377B1 RS20160507A RSP20160507A RS55377B1 RS 55377 B1 RS55377 B1 RS 55377B1 RS 20160507 A RS20160507 A RS 20160507A RS P20160507 A RSP20160507 A RS P20160507A RS 55377 B1 RS55377 B1 RS 55377B1
- Authority
- RS
- Serbia
- Prior art keywords
- compounds
- formula
- pharmaceutically acceptable
- tetrahydro
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000841 | 2012-02-09 | ||
| EP13701703.4A EP2812323B1 (en) | 2012-02-09 | 2013-01-14 | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
| PCT/EP2013/000078 WO2013117288A1 (en) | 2012-02-09 | 2013-01-14 | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55377B1 true RS55377B1 (sr) | 2017-03-31 |
Family
ID=47628092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160507A RS55377B1 (sr) | 2012-02-09 | 2013-01-14 | Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-a |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9339503B2 (https=) |
| EP (1) | EP2812323B1 (https=) |
| JP (1) | JP6116592B2 (https=) |
| KR (1) | KR20140121477A (https=) |
| CN (1) | CN104093714B (https=) |
| AR (1) | AR089944A1 (https=) |
| AU (1) | AU2013218357B2 (https=) |
| BR (1) | BR112014019357A8 (https=) |
| CA (1) | CA2863991C (https=) |
| CL (1) | CL2014002097A1 (https=) |
| CO (1) | CO7020919A2 (https=) |
| DK (1) | DK2812323T3 (https=) |
| EA (1) | EA026611B1 (https=) |
| EC (1) | ECSP14017586A (https=) |
| ES (1) | ES2579980T3 (https=) |
| HR (1) | HRP20160735T1 (https=) |
| HU (1) | HUE029717T2 (https=) |
| IL (1) | IL233984A (https=) |
| MX (1) | MX349736B (https=) |
| NZ (1) | NZ630170A (https=) |
| PE (1) | PE20141823A1 (https=) |
| PH (1) | PH12014501581A1 (https=) |
| PL (1) | PL2812323T3 (https=) |
| PT (1) | PT2812323T (https=) |
| RS (1) | RS55377B1 (https=) |
| SG (1) | SG11201404654SA (https=) |
| SI (1) | SI2812323T1 (https=) |
| TW (1) | TWI572593B (https=) |
| UA (1) | UA116627C2 (https=) |
| WO (1) | WO2013117288A1 (https=) |
| ZA (1) | ZA201406579B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865511A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| PL2938598T3 (pl) | 2012-12-31 | 2017-05-31 | Cadila Healthcare Limited | Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy) |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN105593227A (zh) * | 2013-11-07 | 2016-05-18 | 伊莱利利公司 | 作为端锚聚合酶抑制剂的吡啶并[2,3-d]嘧啶-4-酮化合物 |
| CN106243088B (zh) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| KR101777475B1 (ko) | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018003962A1 (ja) | 2016-06-30 | 2018-01-04 | 国立研究開発法人理化学研究所 | 新規化合物又はその薬理学的に許容される塩 |
| CN108727302A (zh) * | 2017-10-23 | 2018-11-02 | 科迈化工股份有限公司 | 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺（ns）合成工艺 |
| WO2019131798A1 (ja) | 2017-12-27 | 2019-07-04 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| JP7369968B2 (ja) * | 2017-12-27 | 2023-10-27 | 公益財団法人がん研究会 | 抗がん剤 |
| WO2020035031A1 (en) | 2018-08-16 | 2020-02-20 | Genentech, Inc. | Fused ring compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| MXPA06014933A (es) * | 2004-06-30 | 2007-02-28 | Janssen Pharmaceutica Nv | Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1. |
| WO2006094604A1 (en) | 2005-03-11 | 2006-09-14 | Merck Patent Gmbh | Tetrahydro- and dihydroquinazolinones |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
-
2013
- 2013-01-14 KR KR1020147024967A patent/KR20140121477A/ko not_active Ceased
- 2013-01-14 DK DK13701703.4T patent/DK2812323T3/en active
- 2013-01-14 HU HUE13701703A patent/HUE029717T2/en unknown
- 2013-01-14 RS RS20160507A patent/RS55377B1/sr unknown
- 2013-01-14 SI SI201330228A patent/SI2812323T1/sl unknown
- 2013-01-14 EA EA201400879A patent/EA026611B1/ru not_active IP Right Cessation
- 2013-01-14 WO PCT/EP2013/000078 patent/WO2013117288A1/en not_active Ceased
- 2013-01-14 HR HRP20160735TT patent/HRP20160735T1/hr unknown
- 2013-01-14 PL PL13701703.4T patent/PL2812323T3/pl unknown
- 2013-01-14 AU AU2013218357A patent/AU2013218357B2/en active Active
- 2013-01-14 US US14/378,009 patent/US9339503B2/en active Active
- 2013-01-14 MX MX2014009491A patent/MX349736B/es active IP Right Grant
- 2013-01-14 CN CN201380008647.2A patent/CN104093714B/zh active Active
- 2013-01-14 ES ES13701703.4T patent/ES2579980T3/es active Active
- 2013-01-14 NZ NZ630170A patent/NZ630170A/en not_active IP Right Cessation
- 2013-01-14 JP JP2014555963A patent/JP6116592B2/ja active Active
- 2013-01-14 PT PT137017034T patent/PT2812323T/pt unknown
- 2013-01-14 SG SG11201404654SA patent/SG11201404654SA/en unknown
- 2013-01-14 BR BR112014019357A patent/BR112014019357A8/pt not_active Application Discontinuation
- 2013-01-14 UA UAA201409705A patent/UA116627C2/uk unknown
- 2013-01-14 PE PE2014001242A patent/PE20141823A1/es not_active Application Discontinuation
- 2013-01-14 EP EP13701703.4A patent/EP2812323B1/en active Active
- 2013-01-14 CA CA2863991A patent/CA2863991C/en active Active
- 2013-02-08 TW TW102105039A patent/TWI572593B/zh not_active IP Right Cessation
- 2013-02-08 AR ARP130100401A patent/AR089944A1/es unknown
-
2014
- 2014-07-09 PH PH12014501581A patent/PH12014501581A1/en unknown
- 2014-07-30 CO CO14165918A patent/CO7020919A2/es unknown
- 2014-08-06 IL IL233984A patent/IL233984A/en active IP Right Grant
- 2014-08-07 CL CL2014002097A patent/CL2014002097A1/es unknown
- 2014-09-05 EC ECIEPI201417586A patent/ECSP14017586A/es unknown
- 2014-09-08 ZA ZA2014/06579A patent/ZA201406579B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS55377B1 (sr) | Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-a | |
| JP6333450B2 (ja) | （アザ−）イソキノリノン誘導体 | |
| ES2694754T3 (es) | Derivados novedosos de pirrolidina como inhibidores de MetAP-2 | |
| JP5763647B2 (ja) | Ｐｉ３キナーゼの阻害のためのピリジニルイミダゾロン誘導体 | |
| CN103052627B (zh) | 作为fak抑制剂的嘧啶衍生物 | |
| AU2013324681B2 (en) | Quinazolinone derivatives as PARP inhibitors | |
| HK1210470A1 (en) | Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors | |
| WO2012000632A1 (de) | Pyrazolochinoline | |
| CN104066734A (zh) | 三唑并[4,5-d]嘧啶衍生物 | |
| WO2016197078A1 (en) | Compounds for the modulation of myc activity | |
| JP6847942B2 (ja) | 二環式複素環式誘導体 | |
| JP6382964B2 (ja) | フタラジン誘導体 | |
| CN102292339A (zh) | 作为MetAP-2抑制剂的新杂环化合物 | |
| ES2547151T3 (es) | Derivados de 7-azaindol adecuados para el tratamiento de carcinosis | |
| HK1202551B (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| HK1210777B (en) | Quinazolinone derivatives as parp inhibitors | |
| HK1157783A (en) | Thiazolyl piperdine derivatives | |
| HK1209106B (en) | (aza-)isoquinolinone derivatives |